Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells

Authors: Lesley A Mathews, Elaine M Hurt, Xiaohu Zhang, William L Farrar

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

Recently, much attention has been focused on gaining a better understanding of the different populations of cells within a tumor and their contribution to cancer progression. One of the most commonly used methods to isolate a more aggressive sub-population of cells utilizes cell sorting based on expression of certain cell adhesion molecules. A recently established method we developed is to isolate these more aggressive cells based on their properties of increased invasive ability. These more invasive cells have been previously characterized as tumor initiating cells (TICs) that have a stem-like genomic signature and express a number of stem cell genes including Oct3/4 and Nanog and are more tumorigenic compared to their 'non-invasive' counterpart. They also have a profile reminiscent of cells undergoing a classic pattern of epithelial to mesenchymal transition or EMT. Using this model of invasion, we sought to investigate which genes are under epigenetic control in this rare population of cells. Epigenetic modifications, specifically DNA methylation, are key events regulating the process of normal human development. To determine the specific methylation pattern in these invasive prostate cells, and if any developmental genes were being differentially regulated, we analyzed differences in global CpG promoter methylation.

Results

Differentially methylated genes were determined and select genes were chosen for additional analyses. The non-receptor tyrosine kinase BMX and transcription factor SOX1 were found to play a significant role in invasion. Ingenuity pathway analysis revealed the methylated gene list frequently displayed genes from the IL-6/STAT3 pathway. Cells which have decreased levels of the targets BMX and SOX1 also display loss of STAT3 activity. Finally, using Oncomine, it was determined that more aggressive metastatic prostate cancers in humans also have higher levels of both Stat3 and Sox1.

Conclusions

Using this method we can begin to understand which genes are epigenetically regulated in the invasive population compared to the bulk tumor cells. These aggressive sub-populations of cells may be linked to the cancer stem cell hypothesis, making their patterns of epigenetic regulation very attractive for biomarker analysis.
Appendix
Available only for authorised users
Literature
1.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100: 3983-3988. 10.1073/pnas.0530291100PubMedCentralCrossRefPubMed
2.
Graziano A, d'Aquino R, Tirino V, Desiderio V, Rossi A, Pirozzi G: The stem cell hypothesis in head and neck cancer. J Cell Biochem. 2008, 103: 408-412. 10.1002/jcb.21436CrossRefPubMed
3.
Cariati M, Purushotham AD: Stem cells and breast cancer. Histopathology. 2008, 52: 99-107. 10.1111/j.1365-2559.2007.02895.xCrossRefPubMed
4.
Kasper S: Exploring the Origins of the Normal Prostate and Prostate Cancer Stem Cell. Stem Cell Rev. 2008, 4: 193-201. 10.1007/s12015-008-9033-1CrossRefPubMed
5.
6.
Lee CJ, Dosch J, Simeone DM: Pancreatic cancer stem cells. J Clin Oncol. 2008, 26: 2806-2812. 10.1200/JCO.2008.16.6702CrossRefPubMed
7.
Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T, Thomas SB, Farrar WL: Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis. 2009, 26: 433-436. 10.1007/s10585-009-9242-2PubMedCentralCrossRefPubMed
8.
Yu SC, Bian XW: Enrichment of cancer stem cells based on heterogeneity of invasiveness. Stem Cell Rev. 2009, 5: 66-71. 10.1007/s12015-008-9047-8CrossRefPubMed
9.
Sarkar FH, Li Y, Wang Z, Kong D: Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir. 2009, 64: 489-500.PubMedCentralPubMed
10.
Hollier BG, Evans K, Mani SA: The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia. 2009, 14: 29-43. 10.1007/s10911-009-9110-3CrossRefPubMed
11.
Schmalhofer O, Brabletz S, Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009, 28: 151-166. 10.1007/s10555-008-9179-yCrossRefPubMed
12.
Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A: Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 2008, 3: e2888- 10.1371/journal.pone.0002888PubMedCentralCrossRefPubMed
13.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133: 704-715. 10.1016/j.cell.2008.03.027PubMedCentralCrossRefPubMed
14.
Bailey JM, Singh PK, Hollingsworth MA: Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem. 2007, 102: 829-839. 10.1002/jcb.21509CrossRefPubMed
15.
Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, Kirchner T: Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs. 2005, 179: 56-65. 10.1159/000084509CrossRefPubMed
16.
Tsuji T, Ibaragi S, Shima K, Hu MG, Katsurano M, Sasaki A, Hu GF: Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res. 2008, 68: 10377-10386. 10.1158/0008-5472.CAN-08-1444PubMedCentralCrossRefPubMed
17.
Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ: Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005, 8: 393-406. 10.1016/j.ccr.2005.10.001CrossRefPubMed
18.
Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL: CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. 2008, 98: 756-765. 10.1038/sj.bjc.6604242PubMedCentralCrossRefPubMed
19.
Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, Peng Y, Huang CY, Wu HC, Lin CT: Transcription factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression. J Pathol. 2008, 214: 445-455. 10.1002/path.2299CrossRefPubMed
20.
Yamada Y, Tahara M, Miya T, Satoh T, Shirao K, Shimada Y, Ohtsu A, Sasaki Y, Tanigawara Y: Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer. 2008, 98: 1034-1038. 10.1038/sj.bjc.6604271PubMedCentralCrossRefPubMed
21.
Kaukonen J, Lahtinen I, Laine S, Alitalo K, Palotie A: BMX tyrosine kinase gene is expressed in granulocytes and myeloid leukaemias. Br J Haematol. 1996, 94: 455-460.PubMed
22.
Dai B, Kim O, Xie Y, Guo Z, Xu K, Wang B, Kong X, Melamed J, Chen H, Bieberich CJ: Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res. 2006, 66: 8058-8064. 10.1158/0008-5472.CAN-06-1364CrossRefPubMed
23.
Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, Hahm SA, Haider M, Head CS, Reiter RE: Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate. 70: 491-501.
24.
Mulholland DJ, Xin L, Morim A, Lawson D, Witte O, Wu H: Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res. 2009, 69: 8555-8562. 10.1158/0008-5472.CAN-08-4673PubMedCentralCrossRefPubMed
25.
Duhagon MA, Hurt EM, Sotelo-Silveira JR, Zhang X, Farrar WL: Genomic profiling of tumor initiating prostatospheres. BMC Genomics. 11: 324-
26.
Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, Eyler CE, Elderbroom J, Gallagher J, Schuschu J: Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells. 2009, 27: 2393-2404. 10.1002/stem.188PubMedCentralCrossRefPubMed
27.
Sherry MM, Reeves A, Wu JK, Cochran BH: STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells. 2009, 27: 2383-2392. 10.1002/stem.185PubMedCentralCrossRefPubMed
28.
Gao H, Priebe W, Glod J, Banerjee D: Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium. Stem Cells. 2009, 27: 857-865. 10.1002/stem.23CrossRefPubMed
29.
Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, Ressom HW, Rashid A, He AR, Mendelson JS: Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci USA. 2008, 105: 2445-2450. 10.1073/pnas.0705395105PubMedCentralCrossRefPubMed
30.
Daheron L, Opitz SL, Zaehres H, Lensch MW, Andrews PW, Itskovitz-Eldor J, Daley GQ: LIF/STAT3 signaling fails to maintain self-renewal of human embryonic stem cells. Stem Cells. 2004, 22: 770-778. 10.1634/stemcells.22-5-770CrossRefPubMed
31.
Nichane M, Ren X, Bellefroid EJ: Self-regulation of Stat3 activity coordinates cell-cycle progression and neural crest specification. Embo J. 29: 55-67.
32.
Choi SC, Kim SJ, Choi JH, Park CY, Shim WJ, Lim DS: Fibroblast growth factor-2 and -4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K-Akt and ERK1/2 signaling pathways. Stem Cells Dev. 2008, 17: 725-736. 10.1089/scd.2007.0230CrossRefPubMed
33.
Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON: Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci USA. 107: 2610-2615.
34.
Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, Hahm SA, Haider M, Head CS, Reiter RE: Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate. 2009, 70: 491-501.PubMedCentral
35.
Seguin CA, Draper JS, Nagy A, Rossant J: Establishment of endoderm progenitors by SOX transcription factor expression in human embryonic stem cells. Cell Stem Cell. 2008, 3: 182-195. 10.1016/j.stem.2008.06.018CrossRefPubMed
36.
Kan L, Israsena N, Zhang Z, Hu M, Zhao LR, Jalali A, Sahni V, Kessler JA: Sox1 acts through multiple independent pathways to promote neurogenesis. Dev Biol. 2004, 269: 580-594. 10.1016/j.ydbio.2004.02.005CrossRefPubMed
37.
Gao SP, Bromberg JF: Touched and moved by STAT3. Sci STKE. 2006, 2006: pe30- 10.1126/stke.3432006pe30PubMed
38.
Gerhartz C, Heesel B, Sasse J, Hemmann U, Landgraf C, Schneider-Mergener J, Horn F, Heinrich PC, Graeve L: Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J Biol Chem. 1996, 271: 12991-12998. 10.1074/jbc.271.22.12999CrossRefPubMed
39.
Wen X, Lin HH, Shih HM, Kung HJ, Ann DK: Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactivate STAT-mediated gene expression in salivary and lung epithelial cells. J Biol Chem. 1999, 274: 38204-38210. 10.1074/jbc.274.53.38204CrossRefPubMed
40.
Saharinen P, Ekman N, Sarvas K, Parker P, Alitalo K, Silvennoinen O: The Bmx tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase Cdelta. Blood. 1997, 90: 4341-4353.PubMed
41.
Jones PA, Takai D: The role of DNA methylation in mammalian epigenetics. Science. 2001, 293: 1068-1070. 10.1126/science.1063852CrossRefPubMed
42.
Reik W, Collick A, Norris ML, Barton SC, Surani MA: Genomic imprinting determines methylation of parental alleles in transgenic mice. Nature. 1987, 328: 248-251. 10.1038/328248a0CrossRefPubMed
43.
Rugg-Gunn PJ, Ferguson-Smith AC, Pedersen RA: Status of genomic imprinting in human embryonic stem cells as revealed by a large cohort of independently derived and maintained lines. Hum Mol Genet. 2007, 16 (Spec No. 2): R243-251. 10.1093/hmg/ddm245CrossRefPubMed
44.
Wolf SF, Jolly DJ, Lunnen KD, Friedmann T, Migeon BR: Methylation of the hypoxanthine phosphoribosyltransferase locus on the human X chromosome: implications for X-chromosome inactivation. Proc Natl Acad Sci USA. 1984, 81: 2806-2810. 10.1073/pnas.81.9.2806PubMedCentralCrossRefPubMed
45.
Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ: Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008, 451: 141-146. 10.1038/nature06534CrossRefPubMed
46.
Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L: Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008, 10: R10- 10.1186/bcr1855PubMedCentralCrossRefPubMed
47.
Schmidt U, Boucheron N, Unger B, Ellmeier W: The role of Tec family kinases in myeloid cells. Int Arch Allergy Immunol. 2004, 134: 65-78. 10.1159/000078339CrossRefPubMed
48.
Ekman N, Lymboussaki A, Vastrik I, Sarvas K, Kaipainen A, Alitalo K: Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries. Circulation. 1997, 96: 1729-1732.CrossRefPubMed
49.
Ekman N, Arighi E, Rajantie I, Saharinen P, Ristimaki A, Silvennoinen O, Alitalo K: The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner. Oncogene. 2000, 19: 4151-4158. 10.1038/sj.onc.1203763CrossRefPubMed
50.
Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, Schultz PG, Reddy VA: The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA. 2009, 106: 268-273. 10.1073/pnas.0810956106PubMedCentralCrossRefPubMed
51.
Schust J, Sperl B, Hollis A, Mayer TU, Berg T: Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006, 13: 1235-1242. 10.1016/j.chembiol.2006.09.018CrossRefPubMed
52.
Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI: Activated stat-3 in melanoma. Cancer Control. 2008, 15: 196-201.PubMed
53.
Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T: Stat3 promotes metastatic progression of prostate cancer. Am J Pathol. 2008, 172: 1717-1728. 10.2353/ajpath.2008.071054PubMedCentralCrossRefPubMed
54.
Torres-Roca JF, DeSilvio M, Mora LB, Khor LY, Hammond E, Ahmad N, Jove R, Forman J, Lee RJ, Sandler H, Pollack A: Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10. Urology. 2007, 69: 505-509. 10.1016/j.urology.2006.11.006CrossRefPubMed
55.
Sanchez-Ceja SG, Reyes-Maldonado E, Vazquez-Manriquez ME, Lopez-Luna JJ, Belmont A, Gutierrez-Castellanos S: Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma. Lung Cancer. 2006, 54: 163-168. 10.1016/j.lungcan.2006.07.012CrossRefPubMed
56.
Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K: Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 2003, 22: 319-329. 10.1038/sj.onc.1206122CrossRefPubMed
57.
Feng D, Peng C, Li C, Zhou Y, Li M, Ling B, Wei H, Tian Z: Identification and characterization of cancer stem-like cells from primary carcinoma of the cervix uteri. Oncol Rep. 2009, 22: 1129-1134.PubMed
58.
Wilson H, Huelsmeyer M, Chun R, Young KM, Friedrichs K, Argyle DJ: Isolation and characterisation of cancer stem cells from canine osteosarcoma. Vet J. 2008, 175: 69-75. 10.1016/j.tvjl.2007.07.025CrossRefPubMed
59.
Nilsson CL, Dillon R, Devakumar A, Shi SD, Greig M, Rogers JC, Krastins B, Rosenblatt M, Kilmer G, Major M: Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells. J Proteome Res. 9: 430-443.
60.
Abassi YA, Rehn M, Ekman N, Alitalo K, Vuori K: p130Cas Couples the tyrosine kinase Bmx/Etk with regulation of the actin cytoskeleton and cell migration. J Biol Chem. 2003, 278: 35636-35643. 10.1074/jbc.M306438200CrossRefPubMed
61.
Busby JE, Shih SJ, Yang JC, Kung HJ, Evans CP: Angiogenesis is not mediated by prostate cancer neuropeptides. Angiogenesis. 2003, 6: 289-293. 10.1023/B:AGEN.0000029409.94626.64CrossRefPubMed
62.
He Y, Luo Y, Tang S, Rajantie I, Salven P, Heil M, Zhang R, Luo D, Li X, Chi H: Critical function of Bmx/Etk in ischemia-mediated arteriogenesis and angiogenesis. J Clin Invest. 2006, 116: 2344-2355.PubMedCentralPubMed
63.
Pan S, An P, Zhang R, He X, Yin G, Min W: Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol. 2002, 22: 7512-7523. 10.1128/MCB.22.21.7512-7523.2002PubMedCentralCrossRefPubMed
64.
Rajantie I, Ekman N, Iljin K, Arighi E, Gunji Y, Kaukonen J, Palotie A, Dewerchin M, Carmeliet P, Alitalo K: Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. Mol Cell Biol. 2001, 21: 4647-4655. 10.1128/MCB.21.14.4647-4655.2001PubMedCentralCrossRefPubMed
65.
Tu T, Thotala D, Geng L, Hallahan DE, Willey CD: Bone marrow X kinase-mediated signal transduction in irradiated vascular endothelium. Cancer Res. 2008, 68: 2861-2869. 10.1158/0008-5472.CAN-07-5743CrossRefPubMed
66.
Tsai YT, Su YH, Fang SS, Huang TN, Qiu Y, Jou YS, Shih HM, Kung HJ, Chen RH: Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. Mol Cell Biol. 2000, 20: 2043-2054. 10.1128/MCB.20.6.2043-2054.2000PubMedCentralCrossRefPubMed
67.
Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST: Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res. 2008, 68: 3655-3661. 10.1158/0008-5472.CAN-07-2940CrossRefPubMed
68.
Katoh Y, Katoh M: FGF signaling inhibitor, SPRY4, is evolutionarily conserved target of WNT signaling pathway in progenitor cells. Int J Mol Med. 2006, 17: 529-532.PubMed
69.
Bisson I, Prowse DM: WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 2009, 19: 683-697. 10.1038/cr.2009.43CrossRefPubMed
70.
Hurt EM, Chan K, Serrat MA, Thomas SB, Veenstra TD, Farrar WL: Identification of Vitronectin as an Extrinsic Inducer of Cancer Stem Cell Differentiation and Tumor Formation. Stem Cells. 2009, 28: 390-398.
71.
Briscoe J, Pierani A, Jessell TM, Ericson J: A homeodomain protein code specifies progenitor cell identity and neuronal fate in the ventral neural tube. Cell. 2000, 101: 435-445. 10.1016/S0092-8674(00)80853-3CrossRefPubMed
Metadata
Title
Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells
Authors
Lesley A Mathews
Elaine M Hurt
Xiaohu Zhang
William L Farrar
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-267

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Short communication

Epithelial Protein Lost in Neoplasm α (Eplin-α) is transcriptionally regulated by G-actin and MAL/MRTF coactivators

Research

Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma

Research

Regulation of MCP-1 chemokine transcription by p53

Research

Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line

Research

MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β

Research

Integrative analysis of DNA copy number and gene expression in metastatic oral squamous cell carcinoma identifies genes associated with poor survival
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits